1. Home
  2. Press release
Oct 06, 2022 20:16 JST

Source: AIM Vaccine Co., Ltd.

AIM Vaccine, a Major Player in the Chinese Vaccine Industry, Successfully Listed on the Main Board of SEHK

HONG KONG, Oct 06, 2022 - (ACN Newswire) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lot of 200 H shares each. The debut of AIM Vaccine's stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%.

Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited and Macquarie Capital Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCI Asia Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the Joint Bookrunners and Joint Lead Managers. ICBC International Capital Limited is Joint Bookrunner, ICBC International Securities Limited and Livermore Holdings Limited are the Joint Lead Managers.

The Company said that the listing of AIM Vaccine in Hong Kong marks a key milestone and unfolds a new chapter in the Company's development. Looking ahead, AIM Vaccine will continue to strive to access to quality industry resources to expand and optimize its business. The Company will keep abreast of the most advanced platform technologies and innovation trends, accelerating the development of vaccine candidates and continuing to enrich its product portfolio, solidifying and expanding market leadership by increasing sales and marketing efforts for approved vaccine products and commercializing new products, thereby realizing its mission to "develop and manufacture top quality vaccines to safeguard the health of the world", becoming a world-class vaccine company in the global vaccine market and creating greater value for shareholders.


Source: AIM Vaccine Co., Ltd.
Sectors: BioTech, Healthcare & Pharm

Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Release


Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
Nov 08, 2024 10:31 JST

Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field
Nov 07, 2024 18:19 JST

Mitsubishi Motors Acquires Its Own Shares from Nissan
Nov 07, 2024 17:20 JST

Honda Signs Sponsorship Agreement to Provide Electrified Vehicles at World Athletics Championships Tokyo 25
Nov 07, 2024 17:10 JST

Home of Fujitsu joint conservation project designated as first Nationally Certified Sustainably Managed Natural Site in Okinawa
Nov 07, 2024 14:51 JST

NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting
Nov 07, 2024 11:40 JST

Anime Tokyo Station 1st Anniversary Event: Celebrating one year since the opening of the new hub for sharing Japanese anime
Nov 07, 2024 11:00 JST

57% of Banking Executives Struggle with Data Silos, Blocking AI-Driven Personalization, CleverTap's New Report Highlights
Nov 06, 2024 15:30 JST

Honda Unveils Electric Motorcycle Concept Models "EV Fun Concept" and "EV Urban Concept" at EICMA 2024
Nov 06, 2024 14:15 JST

Yoshimoto Kogyo and Mitsubishi Corporation have signed a business partnership agreement for co-creation of business using "laughter"
Nov 06, 2024 11:51 JST

Honda to Begin European Verification Test of Battery Sharing Service with GoCimo
Nov 06, 2024 10:39 JST

Honda Unveils World's First and New V3 Engine with Electrical- Compressor at EICMA 2024
Nov 06, 2024 09:03 JST

Victory and world title for TOYOTA GAZOO Racing
Nov 05, 2024 17:59 JST

Tokyo Stock Exchange and Fujitsu announce renewal of cash equity trading system 'arrowhead4.0'
Nov 05, 2024 17:13 JST

Mitsubishi Heavy Industries Continues Order Intake, Revenue, and Profit Growth in Strong First Half, Raises Full-Year Order Intake Guidance
Nov 05, 2024 14:37 JST

Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 05, 2024 11:35 JST

Asahi Kasei and Honda Sign Shareholders' Agreement to Convert Existing Asahi Kasei Subsidiary into Joint Venture for Production of Lithium-ion Battery Separators in Canada
Nov 04, 2024 14:12 JST

Joby Aviation and Toyota Accelerate Efforts to Realize Air Mobility
Nov 04, 2024 09:36 JST

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Nov 01, 2024 13:56 JST

All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024
Nov 01, 2024 12:43 JST
 More Latest Release >>

Related Release

AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
October 05 2022 18:55 JST
 
AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
September 23 2022 17:06 JST
 
Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
January 12 2022 10:26 JST
 
More Press release >>